Novo Nordisk
NVO
#32
Rank
$232.12 B
Marketcap
$104.90
Share price
-0.87%
Change (1 day)
8.65%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

P/E ratio for Novo Nordisk (NVO)

P/E ratio as of October 2022 (TTM): 30.9

According to Novo Nordisk's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 30.8701. At the end of 2016 the company had a P/E ratio of 16.1.

P/E ratio history for Novo Nordisk from 2001 to 2022

PE ratio at the end of each year

Year P/E ratio Change
201616.1

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.